Positive results announced in phase 1 safety and tolerability study of OLX10212; The study of OliX Pharmaceuticals' investigative property saw encouraging results and helped to identify suitable dosing levels for future clinical trials.

Media coverage

• Title	Positive results announced in phase 1 safety and tolerability study of OLX10212; The study of OliX Pharmaceuticals' investigative property saw encouraging results and helped to identify suitable dosing levels for future clinical trials.
  Media name/outlet	Optometry Times
  Country/Territory	United States
  Date	23.12.1
  Persons	Kichang Lee